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ABSTRACT
Introduction: Asthma is a variable lung condition
whereby patients experience periods of controlled and
uncontrolled asthma symptoms. Patients who experience
prolonged periods of uncontrolled asthma have a higher
incidence of exacerbations and increased morbidity and
mortality rates. The ability to determine and to predict
levels of asthma control and the occurrence of
exacerbations is crucial in asthma management.
Therefore, we aimed to determine to what extent
physiological, behavioural and environmental data,
obtained by mobile healthcare (mHealth) and home-
monitoring sensors, as well as patient characteristics,
can be used to predict episodes of uncontrolled asthma
and the onset of asthma exacerbations.
Methods and analysis: In an 1-year observational
study, patients will be provided with mHealth and home-
monitoring systems to record daily measurements for the
first-month (phase I) and weekly measurements during a
follow-up period of 11 months (phase II). Our study
population consists of 150 patients, aged ≥18 years,
with a clinician’s diagnosis of asthma, currently on
controller medication, with uncontrolled asthma and/or
minimally one exacerbation in the past 12 months. They
will be enrolled over three participating centres, including
Leiden, London and Manchester. Our main outcomes are
the association between physiological, behavioural and
environmental data and (1) the loss of asthma control
and (2) the occurrence of asthma exacerbations.
Ethics: This study was approved by the Medical Ethics
Committee of the Leiden University Medical Center in the
Netherlands and by the NHS ethics service in the UK.
Trial registration number: NCT02774772.
INTRODUCTION
Asthma is one of the most common chronic
diseases worldwide, currently affecting ∼300
million individuals.1 According to the current
asthma guidelines, treatment strategies
should target minimisation of symptoms, opti-
misation of lung function and prevention of
exacerbations while minimising medication
related side-effects.2 Despite wide availability
of effective therapies for asthma, a consider-
able number of patients do not manage to
achieve these proposed targets and experi-
ence a profound burden of disease,3 4 with a
signiﬁcant impact on their quality of life and
on society as a whole.5
Strengths and limitations of this study
▪ This study will assess the early detection of
periods of (un)controlled asthma and the occur-
rence of asthma exacerbations using a wide
variety of novel parameters, such as home-
monitoring systems, sensors and environmental
factors.
▪ Participants in this study are currently being
treated in primary, secondary and tertiary care
centres, and the inclusion and exclusion criteria
are relatively limited, resulting in substantial
external validity.
▪ In the design of this study, not only clinicians
were involved, but we also included engineers
from technical universities, technical and
pharmaceutical companies and representatives of
patients’ organisations, creating a unique envir-
onment of experts, sharing different insights into
problems and potential solutions.
▪ A limitation of this observational study is that if
we manage to establish points of early detection,
a future randomised controlled trial is still
required to assess whether it will improve
asthma outcomes if treatment is adjusted
accordingly.
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There is a plethora of literature advocating the beneﬁ-
cial effect of self-management programmes on asthma
control,2 6 and current guidelines suggest that all partici-
pants with asthma receive education on asthma self-
management.2 Traditional self-management programmes
involve a written plan of action of how to recognise and
respond to worsening asthma. Despite signiﬁcant beneﬁts,
the implementation of self-management programmes in
clinical practice is low, with only one in ﬁve patients report-
ing that they receive a self-management programme7 and
patients’ adherence to self-management programmes is
poor and declines over time.8
Mobile healthcare (mHealth), whether involving mobile
telephone-based interactive systems or internet-based
systems, includes promising tools for supporting asthma
self-management. There is increasing evidence that
mHealth interventions lead to an important and sustained
gain in quality of life, improved clinical outcomes and
support informed and educated patient autonomy.9–12
Thus far, mHealth approaches consisted of one or more of
the following components: an individualised treatment
plan, including self-monitoring and goal setting; medica-
tion management (including alerts and reminders); case-
speciﬁc education; a digital action plan and integration
with the electronic medical record of the healthcare pro-
vider.13 A recent review suggests that current applications
for asthma fail to combine these aspects to a reliable sup-
portive tool.14 This might be due to the fact that asthma is
a complex condition with a heterogeneous presentation,
limiting the usefulness of current mHealth systems to spe-
ciﬁc groups of patients. With the advances in technology, it
is possible to imagine that the next generation of mHealth
systems could be personalised to different asthma pheno-
types and endotypes, making the technology beneﬁcial to
a wider group of individuals. We envisage a system that is
capable of providing personalised recommendations on
asthma management (ie, stepping up or stepping down
treatment) based on patients’ medical history and continu-
ous/regular monitoring of their environment, physiology
and behaviour.
To date, however, it is largely unknown which informa-
tion would be useful in a personalised predictive model.
Therefore, we aim to collect a wide range of clinical,
physiological, behavioural and environmental data using
current mHealth and home-monitoring systems to deter-
mine to which extent they can be used to predict
asthma control and the occurrence of exacerbations.
The results from this research may be used to develop
tailored predictive models and personalised action
points for self-management plans, which can be inte-
grated into mHealth systems, to assist patients with the
self-management of their asthma.
METHODS AND ANALYSIS
Study population
One hundred and ﬁfty patients with a conﬁrmed diag-
nosis of asthma (see box 1 for criteria) will be recruited
from outpatient clinics and general practices in the
regions of London and Manchester in the UK and
Leiden in the Netherlands (50 patients per region). The
inclusion and exclusion criteria are provided in box 1.
Study design
This is an international, multicentre observational study
that will occur alongside participant’s normal asthma
care, as part of the European Union Horizon 2020
funded myAirCoach project. One hundred and ﬁfty
patients with a doctor’s diagnosis of asthma will be
recruited from outpatient clinics and from general prac-
tices in the region of London and Manchester in the
UK and Leiden in the Netherlands (50 patients per
region). Patients will be informed by their pulmonolo-
gist, general practitioner (GP) or practice nurse about
the study. A member of the study group will be available
for additional information.
Participants will be asked to attend their GP and hos-
pital appointments as usual, and continue to take their
medication as recommended by their usual healthcare
team. In addition to their usual care, participants will
attend an introduction visit and complete a 12-month
observational study with two phases (ﬁgure 1):
Box 1 Inclusion and exclusion criteria
Inclusion criteria (all of the following)
▸ Age 18+
▸ Confirmed diagnosis of asthma by either:*
– Reversibility of 12% and/or 200 mL in a spirometry.
– Significant peak flow variability, defined as diurnal peak
expiratory flow amplitude >8%.
– Positive bronchial challenge (any type of bronchial chal-
lenge (MCh, cold air, histamine and hypertonic saline) is
allowed, and cut-offs depend on the selected type).
▸ Asthma treatment steps 2–4†, need for regular treatment with
controller medication (at least 6 months in the previous year).
▸ Either:
– a course of oral prednisone for a minimum of 3 days, or
an emergency department visit/hospitalisation for asthma,
in the previous 12 months or
– current uncontrolled asthma, based on the result of the
Asthma Control Questionnaire.‡
Exclusion criteria (any of the following)
▸ Comorbidities that cause overlapping symptoms such as
breathlessness, wheeze, cough or other interfering chronic
condition.§
▸ Unable to understand English or Dutch, as appropriate.
*Participants without a positive result to any of the above men-
tioned tests will have the opportunity to complete these tests in
order to meet the inclusion criteria.
†According to the Global INitiative for Asthma (GINA) guidelines
criteria.2
‡Defined as an Asthma Control Questionnaire (ACQ) result >1.5.18
§The decision whether or not a patient should be excluded due to
significant comorbidity is to be made by the treating physician.
2 Honkoop PJ, et al. BMJ Open 2017;7:e013935. doi:10.1136/bmjopen-2016-013935
Open Access
group.bmj.com on November 29, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
▸ Introduction visit: all devices and study procedures
are explained.
▸ Phase I: 1-month period of daily monitoring of asthma.
▸ Phase II: 11-month period of weekly monitoring of
asthma. During this phase, a second 2-week period of
daily monitoring will be randomly assigned between
months 2–9, with the purpose to assess the inﬂuence of
exposure during different seasons on patient’s asthma.
The study enrolment is planned to start in September
2016 and the ﬁnal patient is planned to ﬁnish in March
2018.
Outcomes
Main study end points will be:
The association of physiological, behavioural and
environmental data, alone and in combination, with;
▸ Phase I: episodes of (un)controlled asthma (as deter-
mined by the Asthma Control Diary15).
▸ Phase II: occurrence of moderate and severe asthma
exacerbations (as deﬁned by the European
Respiratory Society and American Thoracic Society
(ERS/ATS) Joint Task Force16).
Secondary study end points
▸ User acceptance of mHealth and home-monitoring
systems, as determined by user adherence to measure-
ments and the After-Scenario Questionnaire (ASQ)
feedback.17
▸ The inﬂuence of seasonality on the primary end
points.
Measurements
Measurements will differ between phase I and phase II of
the observational study and are summarised in table 1.
Questionnaires
Asthma control will be measured using the Asthma
Control Diary (ACD)15 for daily measurements or the
Asthma Control Questionnaire (ACQ)18 at screening
and for weekly measurements. Medication usage will be
measured using a custom-designed questionnaire. The
mini Asthma Quality of Life Questionnaire (m-AQLQ19)
will be used to determine the quality of life. Dietary
information will be recorded using the GA2LEN Food
Frequency Questionnaire (FFQ20). Anxiety and depres-
sion will be measured using the Hospital Anxiety and
Depression Scale (HADS21), whereas health behaviour
and insight will be determined using the health
Education Impact Questionnaire (hEIQ22). Upper
airway symptoms will be assessed using the Sino-Nasal
Outcome Test (SNOT-2223) and the usability of all the
devices using the ASQ17. For a detailed description of all
questionnaires, see online supplement.
The occurrence of exacerbations will be assessed
using a daily and weekly custom questionnaire, for phase
I and phase II, respectively. The following deﬁnitions of
exacerbations will be used:16
▸ Severe asthma exacerbations: the occurrence of at least
one of the following:
– Use of systemic corticosteroids (tablets, suspension
or injection), or an increase from a stable main-
tenance dose, for at least 3 days. (For consistency,
courses of corticosteroids separated by 1 week or
more should be registered as separate severe
exacerbations.)
– A hospitalisation or emergency room (ER) visit
because of asthma, requiring systemic
corticosteroids.
Figure 1 Schematic of study
design. At the baseline visit, all
study procedures are explained.
In the first month (phase I),
participants are monitored daily.
Phase II consists of 11 months of
weekly monitoring. Additionally, in
phase II, blocks of patients will be
randomised over months 2–9 for
a second series of 2 weeks of
phase I daily monitoring. Since
participants will be included and
start the study over a 4-month
period, all months will be covered,
which allows the assessment of
the influence of seasonality.
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▸ Moderate asthma exacerbations: the occurrence of at
least one or more of the following:
– deterioration in symptoms,
– deterioration in lung function and
– increased rescue bronchodilator use.
These features should last for 2 days or more, but not
be severe enough to warrant systemic corticosteroid use
and/or hospitalisation. ER visits for asthma (eg, for
routine sick care), not requiring systemic corticosteroids,
will be also classiﬁed as moderate exacerbations.
Clinical tests and home-monitoring/mHealth systems
The following devices will be used during the study:
Piko-1 device, NIOX VERO, X-Halo, Spire, Fitbit HR
Charge and the Smartinhaler.
Participants will use the PIKO-1 device (nSpire Health,
Piko-1 device; available at http://www.nspirehealth.com)
to perform spirometry measurements.
Fraction of exhaled nitric oxide (FeNO) will be
measured at home, in the morning and evening, in a
10 s exhalation manoeuvre using the NIOX-VERO
(Aerocrine, NIOX VERO device; available at http://
www.niox.com/en/). The device is provided to the parti-
cipants for the duration of the study, and it guides parti-
cipants through the manoeuvre audiovisually and gives
an alert when it is performed incorrectly.
Exhaled breath temperature (EBT) will be performed
at home by participants using the X-halo device
(Delmedica, X-Halo device; available at http://www.
x-halo.com/index.php). This device also includes
detailed audiovisual feedback and alerts when used
incorrectly.
The respiratory rate (RR) will be measured using the
Spiro-device (Spire 2015, The Spire device; available at
http://www.spire.io). This device is worn on the belt or
bra and requires no particular action other than
wearing.
Physical activity and heart rate monitoring will be
assessed using the Fitbit HR Charge (Fitbit, Fitbit charge
HR; available at http://www.ﬁtbit.com). This device is
worn on the wrist and automatically collects data.
Medication adherence will be monitored using the
Smartinhaler device (Adherium (NZ) Limited 2013–
2015, Smartinhaler device; available at http://www.
smartinhaler.com). The device records information on
compliance with regular treatment and need of reliever
medications.
Pollen concentrations are measured in the air at the
Leiden University Medical Center. Additionally, it pro-
vides a daily, 5-day pollen forecast, based on pollen con-
centrations in previous years and weather forecast.26 27
In the UK, the Meteorological Ofﬁce (Met Ofﬁce)
Table 1 Study measurements
Introduction visit Phase I Phase II 2 Week—daily monitoring phase
Demographics
Patient characteristics Once – – –
Questionnaires
ACD – Daily – Daily
ACQ Once – Weekly –
Medication diary – Daily Weekly Daily
Exacerbation question – Daily Weekly –
m-AQLQ Once End of phase I Monthly –
GA2LEN FFQ Once – End of phase II –
HADS Once – – –
hEIQ Once – – –
SNOT-22 Once End of phase I Monthly –
ASQ – End of phase I Biannually –
Clinical tests and home-monitoring/mHealth systems
Allergy test Once* – – –
Reversibility test Once* – – –
Spirometry Once Two times per day Weekly Two times per day
FeNO Once Two times per day Weekly Two times per day
Breath temperature Once Two times per day Weekly Two times per day
HR and activity level – Continuous Continuous Continuous
Respiratory rate – Continuous Continuous Continuous
Inhaler usage – Continuous Continuous Continuous
Environmental data – Continuous Continuous Continuous
*Performed if there is no previous test in medical notes. Atopy will be assessed by skin prick tests,24 or measuring levels of specific IgE in
serum. forced expiratory volume in the first second before and after bronchodilation will be assessed using standardised spirometry according
to the ERS criteria.25
ACD, Asthma Control Diary; ACQ, Asthma Control Questionnaire; ASQ, After-Scenario Questionnaire; FeNO, fraction of exhaled nitric oxide;
GA2LEN FFQ, Global Allergy and Asthma European Network Food frequency Questionnaire; HADS, Hospital Anxiety and Depression
Scale; hEIQ, Health Education and Impact Questionnaire; m-AQLQ, mini Asthma Quality of Life Questionnaire; SNOT-22, Sino-Nasal
Outcome Test 22.
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manages a pollen count monitoring network, using
information from their network, weather data and
expertise from organisations such as the National Pollen
and Aerobiological Unit and Pollen UK.28 29 Daily
pollen levels will be recorded at participants’ home and
work postcodes.
The air quality will also be monitored. Measurements
will be assessed in a similar manner in the UK and the
Netherlands. In the UK, the Department for
Environment, Food and Rural Affairs (DEFRA) provides
in-depth information on air quality and air pollution.28
In the Netherlands, the air quality monitoring network
mainly hosted by the Netherlands National Institute for
Public Health and the Environment (RIVM) provides
information on measured air quality at many points
throughout the Netherlands.27 Based on postal codes of
participant’s home address and work address, the appro-
priate measurement station will be selected. The follow-
ing components will be monitored:
▸ PM10: PM10 is a collective term for suspended parti-
cles that can be inhaled, with a maximum diameter
of 0.01 mm. The concentration of ﬁne particulates is
higher around the morning and evening rush hour.
Weather and trafﬁc emissions have a great impact on
the concentration.
▸ PM2.5: PM2.5 is a collective term for suspended parti-
cles that can be inhaled, with a maximum diameter
of 0.0025 mm. Similarly to PM10, the concentration
of ﬁne particulates is higher around the morning and
evening rush hour and dependent on the weather
and trafﬁc emissions. As PM2.5 particles are even
smaller than PM10 particles, they are able to pene-
trate even deeper into the lungs and are therefore
more harmful from a health perspective.
▸ Carbon monoxide: it is formed when a substance is
burned at low oxygen levels. Trafﬁc is a main source
of carbon monoxide in the air.
▸ O3: the concentration of ozone (O3) is an indicator
of the level of smog. The concentration of O3 is
dependent on sun exposure and therefore highest
during good summer weather.
▸ NO2: the concentration of nitrogen dioxide is highly
related to trafﬁc exposure.
Weather conditions and forecast are also collected,
including temperature, humidity, wind speed and fore-
casts. They will be measured at post code level.
Statistical analysis
Statistical methods
Collected data will be analysed with several tools such as
cluster,30 spectral and factor analyses,31 in order to
reveal which parameters allow for the prediction of
periods of uncontrolled asthma. Additionally, we will
perform a similar analysis for phase II of the trial, where
the dependent variable is the onset of (severe) exacerba-
tions. Analyses will be performed in collaboration with
the University of Patras and the Centre for Research
and Technology Hellas (CERTH), who have previous
experience in the handling of these types of continuous
data.32–35 In addition, the anonymised data set will be
input for a clinical state prediction engine and risk
assessment, which will be used in future parts of the
myAirCoach project. Furthermore, a spatial–temporal
model will be generated using artiﬁcial intelligence
methods and data related to user activity and physio-
logical classiﬁcation. Probabilistic techniques, that is,
Bayesian network, will be applied on a provided set of
parameters to give probabilistic prediction of speciﬁc
indicators. Different soft computing, probabilistic and
data mining techniques will be applied on the sensors’
signals/data to provide least error prone analysis and
decision support.
Sample size
This is a single-cohort observational study in which we
aim to assess whether a wide variety of parameters,
alone, or in combination, will be able to predict the
occurrence of either uncontrolled asthma or asthma
exacerbations. As such, we were not able to perform an
appropriate sample size calculation. However, with 150
patients daily monitoring for 6 (4+2) weeks, we will
obtain 150*6*7=6300 daily entries of measurements in
this study. In addition to the daily monitoring, with 150
patients monitoring for 52 weeks, we will obtain 150*52
weeks=7800 weekly entries of measurements in this
study. Furthermore, we also add the total number of
daily/hourly/quarterly data that are automatically gener-
ated by the wearables, including the wristband and the
respiratory rate monitoring device. These amounts of
data should allow for a sufﬁciently conﬁdent prediction.
Data collection
Online questionnaires and home measurement data will
be ﬁlled-in by the patient using the monitoring and
research modules of the self-management support inter-
net application PatientCoach.36 A ‘to do’ list will be avail-
able in PatientCoach speciﬁcally designed for this
research and will provide links to the appropriate ques-
tionnaires and data entry forms at the appropriate
moment (ﬁgure 2A, B). This ‘to do’ list web page will
be preinstalled in an app on an iPod touch 6th gener-
ation (2015 Apple, iPod touch 6, available at http://
www.apple.com). Applications for the Spire, Fitbit HR
and Smartinhaler devices will be preinstalled on the
iPod. Using Bluetooth and Wiﬁ connections, the data
stored on these devices will be regularly transmitted to
and subsequently safely stored within the PatientCoach
system.
Dissemination
We plan to communicate ﬁnal results to participants,
healthcare professionals, policymakers, the funder, the
public and other relevant groups via conferences, publi-
cation or other data sharing arrangements. A ﬁnal study
report will also be send to the Medical Ethics
Committees within 1 year of ﬁnalisation.
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DISCUSSION
Main expected outcome
In the present study, we aim to determine the extent to
which mHealth, home-monitoring sensors and environ-
mental databases can predict (un)controlled asthma
and exacerbations. Initially, we will determine this ability
for each individual device. However, more importantly,
we plan to combine data in order to increase sensitivity
and speciﬁcity, allowing us to determine optimal action
points at which to intervene in order to prevent loss of
control or exacerbations.
Choice of parameters
For the present study, we needed to make a selection of
all currently available sensors and monitoring devices
and for some, like spirometry, FeNO and pollen counts,
this is based on evidence-based criteria. However, our
study aims to be innovative; therefore, a lot of our
devices are new in the management of asthma and are
selected based on their potential value.
We added a spirometry measurement using Piko, since
spirometry is one of the most commonly used measure-
ments in asthma. Also, traditional asthma action plans,
aimed at predicting loss of control or asthma exacerbations,
already involve regular measurements of peak ﬂow or
forced expiratory volume in the ﬁrst second and have been
shown to be beneﬁcial for asthma self-management.37 38
FeNO will be assessed since patients with allergic
airway inﬂammation generally have higher than normal
levels. By measuring FeNO, we aim to evaluate allergic
airway inﬂammation in patients with underlying asthma.
Measuring FeNO during regular control visits to assess
current asthma control has been shown to be effect-
ive,39–42 although there have been some contrasting
results.43–45 Daily monitoring of FeNO might prove to
be of additional value. van der Valk et al46 analysed daily
measurements of FeNO by different types of mathemat-
ical techniques in order to look at periods of exacerba-
tions relative to reference periods in the same patient.
The analysis showed that there are changes in FeNO
before the onset of exacerbations compared to refer-
ence periods. These ﬁndings support that regular FeNO
measurements in the home setting could help to predict
changes in asthma control.
Evaluation of EBT has been suggested as a new
method to detect and monitor pathological processes in
the respiratory system. The putative mechanism of this
approach is based on changes in the blood ﬂow in the
conducting airways that are characteristic of different
disease states, which inﬂuence the temperature of the
exhaled gases. Thus far, associations between EBT on
the one hand and bronchial blood ﬂow, FeNO and
sputum cellular content on the other have been
demonstrated.47
The RR is one of the vital signs and has been an inte-
gral part of the assessment of asthmatic patients in an
acute setting for decades.2 Previous research showed
that variability of RR during sleep is different in asth-
matics.48 Additionally, an increased resting RR during
the day might also indicate loss of asthma control.
Figure 2 (A and B) A view of a
participant’s iPod. In (A), a
general overview of the iPod
screen after turning it on and in
(B), a screenshot of a ‘to do’ list
within the PatientCoach system.
ACQ, Asthma Control
Questionnaire; GA2LEN FFQ,
Global Allergy and Asthma
European Network Food
frequency Questionnaire; HADS,
Hospital Anxiety and Depression
Scale; hEIQ, Health Education
and Impact Questionnaire;
m-AQLQ, mini Asthma Quality of
Life Questionnaire; SNOT-22,
Sino-Nasal Outcome Test 22.
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Therefore, continuous analysis of RR during the day and
while sleeping might prove useful in the prediction of
asthma control.
Pulse rate can be easily measured by currently avail-
able wristbands. The Fitbit additionally assesses activity
level. The added value of monitoring these parameters
in asthma has not been established, yet they potentially
provide relevant information about the clinical state of
asthma including the severity of exacerbations when
evaluated in combination with other clinical outcomes.49
Environmental factors and stimuli have a major impact
on the clinical state of patients with asthma. There is a
clear link between the amount of pollen and deterior-
ation of asthma symptoms in allergic asthmatics.50
Continuous data on exposure to pollen and associated
feedback, especially in established allergies, might aid in
preventing loss of control on asthma.27 51 Furthermore,
other environmental factors, such as air pollution, also
contribute to increased morbidity in asthma, and dimin-
ished lung function in children raised in a polluted envir-
onment.52 53 Finally, certain weather conditions might
also prove to be relevant for predicting asthma control.
Future implications
This study is part of the European Union Horizon 2020
funded myAirCoach project. The ﬁnal aim of this
project is to develop a holistic mHealth personalised
asthma-monitoring system empowering patients to
manage their own health by providing user-friendly tools
to increase the awareness of their clinical state and
effectiveness of medical treatment. To this purpose, a
large consortium of leading clinicians in the ﬁeld of
asthma, engineers from technical universities, technical
and pharmaceutical companies and representatives of
patients’ organisations was assembled, creating a unique
environment of highly qualiﬁed experts, sharing differ-
ent insights into problems and potential solutions a
project such as this poses. In the present study, data
from a wide variety of measurements, including sensors,
home-monitoring systems and environmental databases,
are collected and patients still need to manually report
current symptoms and occurrence of exacerbations on
questionnaires on their iPod. This requires intensive
entry of questionnaires by patients in this phase of the
entire myAirCoach project. This is needed to determine
the association between symptoms/exacerbations and
data from each of these measurements separately and
combinations between measurements. However, if we
manage to establish associations, manual entry of ques-
tionnaires is no longer required. We might use these
established associations in our ﬁnal model to predict
asthma control and exacerbations, by real-time analysis
of automatically collected continuous measurements
from individual patients. We envisage a ﬁnal system,
where people with asthma will only be required to wear
certain sensors and they will receive automated, persona-
lised feedback via an app, for instance on their mobile
phone. A ‘personal mHealth guidance system’ will
empower patients to customise their treatment towards
personalised preset goals and guidelines, either automat-
ically or driven by healthcare professional. In this
context, myAirCoach will give to clinicians early indica-
tions of increasing symptoms or exacerbations, while
making an important contribution in successful self-
management of asthma.
Additionally, in another part of the myAirCoach study,
we are seeking to obtain end-user (people with asthma
and healthcare professionals) opinions on the uses and
applications of mHealth, in collaboration with patient-
focused groups (asthma UK and The European
Federation of Allergy and Airways Diseases Patients’
Associations (EFA)), and will take these opinions into
account in the design of the ﬁnal prototype.
Besides the obvious necessity of the current study to
ground the ﬁnal myAirCoach framework with data,
these results are also expected to lead to increased conﬁ-
dence in the myAirCoach approach and in online deci-
sion support and self-management systems in general.
The impact of such a holistic and innovative approach is
huge, and the foundations laid here are expected to
result in a widespread adoption of sensor-based self-
management systems not only in asthma, but also in
other respiratory diseases.
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